Malaysia's Pharmaniaga signs Covid vaccine agreement with China's Sinovac
[KUALA LUMPUR] Malaysia Pharmaniaga has signed an agreement with China's Sinovac to purchase ready-to-fill Covid-19 vaccines and later to manufacture the vaccine domestically, it said on Tuesday.
Pharmaniaga said in a filing to the bourse that the company will carry out a fill-and-finish process of the vaccine in Malaysia, and will subsequently enter into local manufacturing, under license from Sinovac for its technology and know-how.
"This will also help Pharmaniaga in long-term partnerships, including technology transfer to grow the sector in Malaysia," the company said.
Malaysia has been in talks to secure a total of 23.9 million doses of Covid-19 vaccines from Sinovac and another Chinese manufacturer CanSino Biologics, and from Russia's Gamaleya Institute, the maker of the Sputnik V vaccine.
The South-east Asian nation has also procured coronavirus vaccines from US and German drugmakers Pfizer and BioNTech, as well as British-Swedish biopharmaceutical firm AstraZeneca.
REUTERS
A NEWSLETTER FOR YOU
Asean Business
Business insights centering on South-east Asia's fast-growing economies.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
International
US births retreat after pandemic-era growth
Markets are embracing India's Modi for what he won’t do
Blinken to meet businesses in Shanghai as he kicks off a tough China trip
Indonesia’s central bank surprises with ‘pre-emptive’ rate hike to cushion falling rupiah
South Korea’s economic growth beats forecast as exports rise
China 2024 growth outlook raised to 4.8%, deflation risk lingers